AIMS: Superficial CD34-positive fibroblastic tumor (SCD34FT) and PRDM10-rearranged soft tissue tumor (PRDM10-STT) are rare mesenchymal tumors. These lesions have clinicopathological similarities, but their relationship remains controversial. This study aimed to characterise a series of cases of SCD34FT and PRDM10-STT. METHODS AND RESULTS: Ten lesions each of SCD34FT and PRDM10-STT were studied using immunohistochemistry, array-comparative genomic hybridisation (aCGH), RNA sequencing and exome sequencing. Tumors mainly occurred in young adults, were generally small (< 5 cm) and arose predominantly in the superficial soft tissues of the lower extremities. Follow-up data were available in 15 cases (SCD34FT, n = 7, median 16 months; PRDM10-STT, n = 8, median 14 months), local recurrences occurred in four cases (SCD34FT, two of 10; PRDM10-STT, two of 10), while no distant spread was documented. Morphologically, tumors were relatively well-circumscribed and composed of sheets and fascicles of spindle and pleomorphic cells showing low mitotic activity (< 1/mm²) without necrosis. Other findings included: granular cell change, lipoblast-like cells, ectatic blood vessels with fibrinous material, myxoid stromal changes, metaplastic bone and increased mitotic activity (> 1/mm²). All tumors diffusely expressed CD34, while pan-keratin and desmin were commonly seen focally. SynCAM3 was diffusely expressed in 12 cases (SCD34FT, n = 5; PRDM10-STT, n = 7), independently of fusion status. aCGH profiles were 'flat' (PRDM10-STT, n = 4; SCD34FT, n = 2) and exome sequencing showed no recurrent pathogenic mutations (PRDM10-STT, n = 2; SCD34FT, n = 4). Overall, the only morphological features seen exclusively in PRDM10-STT were myxoid stromal changes (three of 10) and metaplastic bone (two of 10). CONCLUSION: We expand the current knowledge on PRDM10-STT and SCD34FT and provide additional evidence for considering them as overlapping entities.

Department of Bioinformatics Institut Bergonié Bordeaux France

Department of Biopathology Centre Leon Berard Lyon France

Department of Biopathology Institut Bergonié Bordeaux France

Department of Pathology and Molecular Genetics Bioptical Laboratory Ltd Plzen Czech Republic

Department of Pathology Faculty of Medicine in Plzen Charles University Plzen Czech Republic

Department of Pathology Strasbourg Regional University Hospital Strasbourg France

Department of Pathology Warwick Hospital Warwick UK

Department of Tumor Biology and Pathology Molecular Biology Unit Centre Georges François Leclerc Dijon France

Department of Tumor Biology and Pathology Pathology Unit Centre Georges François Leclerc Dijon France

INSERM U1218 Action Unit Bordeaux France

Université Lyon Claude Bernard Lyon 1 University Lyon France

University of Bordeaux Talence France

See more in PubMed

Carter JM, Weiss SW, Linos K, DiCaudo DJ, Folpe AL. Superficial CD34-positive fibroblastic tumor: report of 18 cases of a distinctive low-grade mesenchymal neoplasm of intermediate (borderline) malignancy. Mod. Pathol 2014; 27; 294-302.

World Health Organisation (WHO). Classification of Tumours Editorial Board. Soft tissue and bone tumours. Lyon: International Agency for Research on Cancer, 2020.

Puls F, Pillay N, Fagman H et al. PRDM10-rearranged soft tissue tumor: a clinicopathologic study of 9 cases. Am. J. Surg. Pathol 2018; 43; 504-513.

Hofvander J, Puls F, Pillay N et al. Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile. J. Pathol 2019; 249; 425-434.

Hofvander J, Tayebwa J, Nilsson J et al. Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma. Clin. Cancer Res 2015; 21; 864-869.

Le Loarer F, Cleven AHG, Bouvier C et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod. Pathol 2020; 33; 404-419.

Michal M, Rubin BP, Kazakov DV et al. Inflammatory leiomyosarcoma shows frequent co-expression of smooth and skeletal muscle markers supporting a primitive myogenic phenotype: a report of 9 cases with a proposal for reclassification as low-grade inflammatory myogenic tumor. Virchows Arch 2020; 477; 219-230.

Karanian M, Kelsey A, Paindavoine S et al. SRF fusions other than with RELA expand the molecular definition of SRF-fused perivascular tumors. Am. J. Surg. Pathol 2020; 44; 1725-1735.

Hendry SA, Wong DD, Papadimitriou J, Robbins P, Wood BA. Superficial CD34-positive fibroblastic tumour: report of two new cases. Pathology 2015; 47; 479-482.

Lao IW, Yu L, Wang J. Superficial CD34-positive fibroblastic tumour: a clinicopathological and immunohistochemical study of an additional series. Histopathology 2017; 70; 394-401.

Batur S, Ozcan K, Ozcan G, Tosun I, Comunoglu N. Superficial CD34 positive fibroblastic tumor: report of three cases and review of the literature. Int. J. Dermatol 2019; 58; 416-422.

Mao X, Sun YY, Deng ML, Ma T, Yu L. Superficial CD34-positive fibroblastic tumor: report of two cases and review of literature. Int. J. Clin. Exp. Pathol 2020; 13; 38-43.

Carter JM, Sukov WR, Montgomery E et al. TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms. Am. J. Surg. Pathol 2014; 38; 1182-1192.

Zreik RT, Carter JM, Sukov WR et al. TGFBR3 and MGEA5 rearrangements are much more common in ‘hybrid’ hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study. Hum. Pathol 2016; 53; 14-24.

Antonescu CR, Zhang L, Nielsen GP, Rosenberg AE, Dal Cin P, Fletcher CD. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer 2011; 50; 757-764.

Mohajeri A, Kindblom L-G, Sumathi VP et al. SNP array and FISH findings in two pleomorphic hyalinizing angiectatic tumors. Cancer Genet 2012; 205; 673-676.

Laskin WB, Fetsch JF, Miettinen M. Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome. Am. J. Surg. Pathol 2014; 38; 1-12.

Hallor KH, Sciot R, Staaf J et al. Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J. Pathol 2009; 217; 716-727.

Kao Y-C, Ranucci V, Zhang L et al. Recurrent BRAF gene rearrangements in myxoinflammatory fibroblastic sarcomas, but not hemosiderotic fibrolipomatous tumors. Am. J. Surg. Pathol 2017; 41; 1456-1465.

Park J-A, Kim KC. Expression patterns of PRDM10 during mouse embryonic development. BMB Rep 2010; 43; 29-33.

Han BY, Seah MKY, Brooks IR et al. Global translation during early development depends on the essential transcription factor PRDM10. Nat. Commun 2020; 11; 3603.

Rostami-Nejad M, Mansouri V, Mahmoud Robati R, Mohaghegh Shalmani H, Mahmoudi Lamouki R, Rezaei TM. Network analysis of grade II into grade III transition in rectum cancer patients. Gastroenterol. Hepatol. Bed Bench 2018; 11; S118-S123.

Lou W, Liu J, Ding B, Xu L, Fan W. Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Manag. Res 2018; 10; 4747-4757.

Wu K, Yin X, Jin Y, Liu F, Gao J. Identification of aberrantly methylated differentially expressed genes in prostate carcinoma using integrated bioinformatics. Cancer Cell Int 2019; 5(19); 51.

Florek AG, Amin SM, Guitart J, Krunic AL. Superficial CD34-positive fibroblastic tumor successfully treated with Mohs micrographic surgery. Dermatol. Surg 2018; 44; 313-315.

Tejwani A, Kobayashi W, Chen Y-L et al. Management of acral myxoinflammatory fibroblastic sarcoma. Cancer 2010; 116; 5733-5739.

Update on cutaneous mesenchymal tumors in the 5th edition of WHO classification of skin tumors with an emphasis on new fusion-associated neoplasms